Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors

  • Neeb, Antje
  • Herranz Martín, Nicolás
  • Arce-Gallego, Sara
  • Buroni, Lorenzo
  • Athie Cuervo, Alejandro
  • Casanova Salas, Irene
  • González Rodríguez, Macarena
  • Morales Barrera, Rafael
  • Suárez Rodríguez, Cristina
  • Carles Galceran, Joan
  • Serra Elizalde, Violeta
  • Mateo Valderrama, Joaquim
  • Miranda, Susana
  • Cordoba, Sarai
  • Castro, Natalia
  • Yuan, Wei
  • Casals, Teresa
Inhibició de l’ATR; Resposta de danys a l’ADN; Càncer de pròstata, Inhibición de ATR; Respuesta al daño del ADN; Cancer de prostata, ATR inhibition; DNA damage response; Prostate cancer, Background Deleterious ATM alterations are found in metastatic prostate cancer (PC); PARP inhibition has antitumour activity against this subset, but only some ATM loss PCs respond. Objective To characterise ATM-deficient lethal PC and to study synthetic lethal therapeutic strategies for this subset. Design, setting, and participants We studied advanced PC biopsies using validated immunohistochemical (IHC) and next-generation sequencing (NGS) assays. In vitro cell line models modified using CRISPR-Cas9 to impair ATM function were generated and used in drug-sensitivity and functional assays, with validation in a patient-derived model. Outcome measurements and statistical analysis ATM expression by IHC was correlated with clinical outcome using Kaplan-Meier curves and log-rank test; sensitivity to different drug combinations was assessed in the preclinical models. Results and limitations Overall, we detected ATM IHC loss in 68/631 (11%) PC patients in at least one biopsy, with synchronous and metachronous intrapatient heterogeneity; 46/71 (65%) biopsies with ATM loss had ATM mutations or deletions by NGS. ATM IHC loss was not associated with worse outcome from advanced disease, but ATM loss was associated with increased genomic instability (NtAI:number of subchromosomal regions with allelic imbalance extending to the telomere, p = 0.005; large-scale transitions, p = 0.05). In vitro, ATM loss PC models were sensitive to ATR inhibition, but had variable sensitivity to PARP inhibition; superior antitumour activity was seen with combined PARP and ATR inhibition in these models. Conclusions ATM loss in PC is not always detected by targeted NGS, associates with genomic instability, and is most sensitive to combined ATR and PARP inhibition., We gratefully acknowledge research funding for this work from Cancer Research UK, Prostate Cancer UK, the Movember Foundation through the London Movember Centre of Excellence ( CEO13_2-002 ), the Prostate Cancer Foundation (including Young Investigator Awards to Joaquin Mateo, Pasquale Rescigno, and Adam Sharp), Stand Up To Cancer, and the UK Department of Health through an Experimental Cancer Medicine Centre grant. Professor Johann de Bono is a National Institute for Health Research (NIHR) Senior Investigator; research at the Royal Marsden Hospital is supported by a Biomedical Research Centre grant. Part of this work was also funded by a Deparment of Defense CDMRP Impact Award (W81XWH-18-1-0756) to Joaquin Mateo and by Instituto de Salud Carlos III through Grant FI19/00280 to Sara Arce-Gallego, Grant CP19/00170 to Nicolás Herranz, and Grant PI18/01384 to Joaquin Mateo. The authors affiliated to VHIO acknowledge the “la Caixa” Foundation ( ID 100010434 ) for funding under agreement LCF/PR/PR17/51120011 and funding from Fundacion FERO and Moventia . This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement 837900 . The funding organisations had no role in the design, conduction or data analysis of this project, neither in the manuscript preparation.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Cyclophilin D plays a critical role in the survival of senescent cells

  • Protasoni, Margherita
  • López Polo, Vanessa
  • Stephan-Otto Attolini, Camille
  • Herranz Martín, Nicolás
  • Brandariz, Julian
  • Mateo, Joaquin
Senescencia celular; Ciclofilina D; Mitocondrias, Senescència cel·lular; Ciclofilina D; Mitocondris, Cellular senescence; Cyclophilin D; Mitochondria, Senescent cells play a causative role in many diseases, and their elimination is a promising therapeutic strategy. Here, through a genome-wide CRISPR/Cas9 screen, we identify the gene PPIF, encoding the mitochondrial protein cyclophilin D (CypD), as a novel senolytic target. Cyclophilin D promotes the transient opening of the mitochondrial permeability transition pore (mPTP), which serves as a failsafe mechanism for calcium efflux. We show that senescent cells exhibit a high frequency of transient CypD/mPTP opening events, known as 'flickering'. Inhibition of CypD using genetic or pharmacologic tools, including cyclosporin A, leads to the toxic accumulation of mitochondrial Ca2+ and the death of senescent cells. Genetic or pharmacological inhibition of NCLX, another mitochondrial calcium efflux channel, also leads to senolysis, while inhibition of the main Ca2+ influx channel, MCU, prevents senolysis induced by CypD inhibition. We conclude that senescent cells are highly vulnerable to elevated mitochondrial Ca2+ ions, and that transient CypD/mPTP opening is a critical adaptation mechanism for the survival of senescent cells., MP was supported by the European Union’s Horizon 2021 research and innovation programme under the Marie Sklodowska-Curie grant agreement (HORIZON-MSCA-2021-PF-01) and the Barcelona Institute of Science and Technology (BIST). VLP was recipient of a predoctoral contract from Spanish Ministry of Education (FPU-18/05917). JB, NH, and JM work was funded by the Asociación Española Contra el Cancer (AECC; PRYCO211023SERR) and by the Instituto de Salud Carlos III (CP19/00170). SR was funded by the NIH Intramural Research Program. MK was funded by the Barcelona Institute of Science and technology (BIST) and Asociación Española Contra el Cáncer (AECC; POSTD18020SERR) and supported by the European Molecular Biology Organization (EMBO). Work in the laboratory of MS was funded by the IRB and “laCaixa” Foundation, by a Coordinated-AECC grant (PRYCO211023SERR), and by Secretaria d’Universitats i Recerca del Departament d’Empresa i Coneixement of Catalonia (Grup de Recerca consolidat 2017 SGR 282).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Cyclophilin D plays a critical role in the survival of senescent cells

  • Protasoni, Margherita
  • López Polo, Vanessa
  • Stephan-Otto Attolini, Camille
  • Herranz Martín, Nicolás
  • Brandariz, Julian
  • Mateo, Joaquin
Senescencia celular; Ciclofilina D; Mitocondrias, Senescència cel·lular; Ciclofilina D; Mitocondris, Cellular senescence; Cyclophilin D; Mitochondria, Senescent cells play a causative role in many diseases, and their elimination is a promising therapeutic strategy. Here, through a genome-wide CRISPR/Cas9 screen, we identify the gene PPIF, encoding the mitochondrial protein cyclophilin D (CypD), as a novel senolytic target. Cyclophilin D promotes the transient opening of the mitochondrial permeability transition pore (mPTP), which serves as a failsafe mechanism for calcium efflux. We show that senescent cells exhibit a high frequency of transient CypD/mPTP opening events, known as 'flickering'. Inhibition of CypD using genetic or pharmacologic tools, including cyclosporin A, leads to the toxic accumulation of mitochondrial Ca2+ and the death of senescent cells. Genetic or pharmacological inhibition of NCLX, another mitochondrial calcium efflux channel, also leads to senolysis, while inhibition of the main Ca2+ influx channel, MCU, prevents senolysis induced by CypD inhibition. We conclude that senescent cells are highly vulnerable to elevated mitochondrial Ca2+ ions, and that transient CypD/mPTP opening is a critical adaptation mechanism for the survival of senescent cells., MP was supported by the European Union’s Horizon 2021 research and innovation programme under the Marie Sklodowska-Curie grant agreement (HORIZON-MSCA-2021-PF-01) and the Barcelona Institute of Science and Technology (BIST). VLP was recipient of a predoctoral contract from Spanish Ministry of Education (FPU-18/05917). JB, NH, and JM work was funded by the Asociación Española Contra el Cancer (AECC; PRYCO211023SERR) and by the Instituto de Salud Carlos III (CP19/00170). SR was funded by the NIH Intramural Research Program. MK was funded by the Barcelona Institute of Science and technology (BIST) and Asociación Española Contra el Cáncer (AECC; POSTD18020SERR) and supported by the European Molecular Biology Organization (EMBO). Work in the laboratory of MS was funded by the IRB and “laCaixa” Foundation, by a Coordinated-AECC grant (PRYCO211023SERR), and by Secretaria d’Universitats i Recerca del Departament d’Empresa i Coneixement of Catalonia (Grup de Recerca consolidat 2017 SGR 282).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors

  • Neeb, Antje
  • Herranz Martín, Nicolás
  • Arce Gallego, Sara
  • Buroni, Lorenzo
  • Athie Cuervo, Alejandro
  • Casanova Salas, Irene
  • González Rodríguez, Macarena
  • Morales Barrera, Rafael
  • Suárez Rodríguez, Cristina
  • Carles Galceran, Joan
  • Serra Elizalde, Violeta
  • Mateo Valderrama, Joaquim
  • Miranda, Susana
  • Cordoba, Sarai
  • Castro, Natalia
  • Yuan, Wei
  • Casals, Teresa
Inhibició de l’ATR; Resposta de danys a l’ADN; Càncer de pròstata, Inhibición de ATR; Respuesta al daño del ADN; Cancer de prostata, ATR inhibition; DNA damage response; Prostate cancer, Background Deleterious ATM alterations are found in metastatic prostate cancer (PC); PARP inhibition has antitumour activity against this subset, but only some ATM loss PCs respond. Objective To characterise ATM-deficient lethal PC and to study synthetic lethal therapeutic strategies for this subset. Design, setting, and participants We studied advanced PC biopsies using validated immunohistochemical (IHC) and next-generation sequencing (NGS) assays. In vitro cell line models modified using CRISPR-Cas9 to impair ATM function were generated and used in drug-sensitivity and functional assays, with validation in a patient-derived model. Outcome measurements and statistical analysis ATM expression by IHC was correlated with clinical outcome using Kaplan-Meier curves and log-rank test; sensitivity to different drug combinations was assessed in the preclinical models. Results and limitations Overall, we detected ATM IHC loss in 68/631 (11%) PC patients in at least one biopsy, with synchronous and metachronous intrapatient heterogeneity; 46/71 (65%) biopsies with ATM loss had ATM mutations or deletions by NGS. ATM IHC loss was not associated with worse outcome from advanced disease, but ATM loss was associated with increased genomic instability (NtAI:number of subchromosomal regions with allelic imbalance extending to the telomere, p = 0.005; large-scale transitions, p = 0.05). In vitro, ATM loss PC models were sensitive to ATR inhibition, but had variable sensitivity to PARP inhibition; superior antitumour activity was seen with combined PARP and ATR inhibition in these models. Conclusions ATM loss in PC is not always detected by targeted NGS, associates with genomic instability, and is most sensitive to combined ATR and PARP inhibition., We gratefully acknowledge research funding for this work from Cancer Research UK, Prostate Cancer UK, the Movember Foundation through the London Movember Centre of Excellence ( CEO13_2-002 ), the Prostate Cancer Foundation (including Young Investigator Awards to Joaquin Mateo, Pasquale Rescigno, and Adam Sharp), Stand Up To Cancer, and the UK Department of Health through an Experimental Cancer Medicine Centre grant. Professor Johann de Bono is a National Institute for Health Research (NIHR) Senior Investigator; research at the Royal Marsden Hospital is supported by a Biomedical Research Centre grant. Part of this work was also funded by a Deparment of Defense CDMRP Impact Award (W81XWH-18-1-0756) to Joaquin Mateo and by Instituto de Salud Carlos III through Grant FI19/00280 to Sara Arce-Gallego, Grant CP19/00170 to Nicolás Herranz, and Grant PI18/01384 to Joaquin Mateo. The authors affiliated to VHIO acknowledge the “la Caixa” Foundation ( ID 100010434 ) for funding under agreement LCF/PR/PR17/51120011 and funding from Fundacion FERO and Moventia . This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement 837900 . The funding organisations had no role in the design, conduction or data analysis of this project, neither in the manuscript preparation.